| 6.44 -0.47 (-6.8%) | 08-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.76 |
1-year : | 8.51 |
| Resists | First : | 6.65 |
Second : | 7.28 |
| Pivot price | 6.66  |
|||
| Supports | First : | 5.61 |
Second : | 4.67 |
| MAs | MA(5) : | 6.9 |
MA(20) : | 6.46 |
| MA(100) : | 6.67 |
MA(250) : | 7.31 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 62.3 |
D(3) : | 79.2 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 9.42 | Low : | 5.44 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GYRE ] has closed above bottom band by 29.4%. Bollinger Bands are 15.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.9 - 6.95 | 6.95 - 6.98 |
| Low: | 6.34 - 6.39 | 6.39 - 6.43 |
| Close: | 6.37 - 6.45 | 6.45 - 6.51 |
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Wed, 19 Aug 2026
GYRE | Gyre Therapeutics, Inc. Common Financials - Revenue Breakdown - Quiver Quantitative
Fri, 07 Aug 2026
Gyre Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Fri, 07 Aug 2026
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview - TradingView
Fri, 07 Aug 2026
About $300M Cullgen deal adds cancer candidates to Gyre's pipeline - Stock Titan
Fri, 07 Aug 2026
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 106 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 74.4 (%) |
| Held by Institutions | 8.1 (%) |
| Shares Short | 1,820 (K) |
| Shares Short P.Month | 1,830 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.01 |
| Profit Margin | -19.4 % |
| Operating Margin | -47.7 % |
| Return on Assets (ttm) | -5.5 % |
| Return on Equity (ttm) | -17.5 % |
| Qtrly Rev. Growth | -2.1 % |
| Gross Profit (p.s.) | 0.97 |
| Sales Per Share | 1.03 |
| EBITDA (p.s.) | -0.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -30.67 |
| PEG Ratio | 0 |
| Price to Book value | 6.31 |
| Price to Sales | 6.21 |
| Price to Cash Flow | -138.51 |
| Dividend | 3.59 |
| Forward Dividend | 0 |
| Dividend Yield | 55.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|